
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc. demonstrated significant financial growth, with total revenue increasing by 84.7% year-over-year, driven primarily by a remarkable 117.2% growth in Genomics revenue, which reached $252.9 million. The company is poised to benefit from higher average selling prices (ASPs) due to an anticipated shift towards more premium offerings, including the xF liquid biopsy assay and the xT CDx test, which are expected to enhance profitability. Additionally, the continued expansion of oncology testing volumes and the potential for securing reimbursement in the minimal residual disease segment indicate a robust growth trajectory for Tempus AI's business model.
Bears say
Tempus AI Inc. has experienced a decline in gross margins within the Data & Other segment, decreasing from 76.8% in Q3 of the previous year to 69.7% in Q3 of the current reporting period. Additionally, the company faces significant financial risks, including lower-than-anticipated sales growth due to competitive pressures and regulatory hurdles, as well as ongoing substantial losses and debt that may hinder its ability to achieve sustainable profitability. Despite a revenue increase to $334.2 million, the adjusted EBITDA was notably below both internal estimates and consensus expectations, highlighting potential challenges in operational efficiency and revenue generation moving forward.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares